Product Description
Chloroquine phosphate is used to prevent and treat malaria. It is also used to treat amebiasis. Chloroquine phosphate is in a class of drugs called antimalarials and amebicides. It works by killing the organisms that cause malaria and amebiasis. (Sourced from: https://medlineplus.gov/druginfo/meds/a682318.html)
Mechanisms of Action: Ubiquitin Ligase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | France | Greece | Hong Kong | Hungary | India | Ireland | Jordan | Korea | Lebanon | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Adenocarcinoma|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| The Seven Trial | P1 |
Not yet recruiting |
Pancreatic Cancer|Adenocarcinoma |
2025-06-01 |